Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.06
−$0.095 · -4.41%
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Previous close
$2.06
−$0.095 · -4.41%
Regular session · ET · Market data may be delayed.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Day range
Current $2.06
52-week range
Current $2.06
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
54
Mixed
Risk
74
High Risk
Momentum
55
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Day range
Current $2.06
52-week range
Current $2.06
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 534.86K USD | 516.75K USD | 98.61K USD | 42.47K USD |
| Gross profit | — | −534.86K USD | −516.75K USD | −98.61K USD | −42.47K USD |
| Research and development | 13.42M USD | 9.62M USD | 12.26M USD | 10.23M USD | 2.75M USD |
| Selling, general, and administrative | 5.77M USD | 5.51M USD | 6.64M USD | 8.33M USD | 3.35M USD |
| Operating expenses | 27.98M USD | 15.13M USD | 18.9M USD | 18.57M USD | 6.11M USD |
| Interest income | 79.2K USD | 684 USD | 5.29K USD | 20.41K USD | 664 USD |
| Interest expense | 6.62K USD | 26.81K USD | 55.9K USD | 17.56M USD | 95.07K USD |
| Depreciation and amortization | 114.18K USD | 534.86K USD | 516.75K USD | 98.61K USD | 42.47K USD |
| Operating income | −27.98M USD | −15.66M USD | −19.42M USD | −18.67M USD | −6.15M USD |
| Net income | −34.66M USD | −16.75M USD | −18.55M USD | −17.56M USD | −6.84M USD |
Company facts updated Sep 7, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 15, 2025 | 1:28 | — | — |
Stock split | Dec 4, 2024 | 1:33 | — | — |
Stock split | Jan 16, 2024 | 1:40 | — | — |
Stock split | May 23, 2023 | 1:20 | — | — |
Effective May 15, 2025
1:28
Effective Dec 4, 2024
1:33
Effective Jan 16, 2024
1:40
Effective May 23, 2023
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
